• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Anteris Technologies Global Corp. filed SEC Form 8-K: Leadership Update

    6/9/25 7:00:37 AM ET
    $AVR
    Industrial Specialties
    Health Care
    Get the next $AVR alert in real time by email
    false000201151400020115142025-06-092025-06-09

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 8-K



    CURRENT REPORT
    Pursuant to Section 13 OR 15(d)
    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 9, 2025



    Anteris Technologies Global Corp.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-42437 99-1407174
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    Toowong Tower, Level 3, Suite 302
    9 Sherwood Road
    Toowong, QLD
    Australia
      4066
    (Address of Principal Executive Offices)
     
    (Zip Code)

    Registrant’s telephone number, including area code: +61 7 3152 3200

    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, par value $0.0001 per share
     
    AVR
      The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02.
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     Appointment of Mr. David Roberts and Mr. Gregory Moss to the Board of Directors

    On June 7, 2025 (June 8, 2025 in Australia), the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Mr. Gregory Moss and Mr. David Roberts to serve on the Board. Mr. Moss will serve as a Class I Director, with a term expiring at the Company's 2025 annual meeting of stockholders and will serve on the Nominating and Corporate Governance Committee of the Board. Mr. Roberts will serve as a Class III Director, with a term expiring at the Company’s 2027 annual meeting of stockholders and will serve on the Audit and Risk Committee and the Compensation Committee of the Board.

    Mr. Gregory Moss, age 41, serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon’s $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes.

    Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia.

    Mr. David Roberts, age 61, is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc.

    There are no understandings or arrangements between Mr. Moss and Mr. Roberts and any other person pursuant to which Mr. Moss  or Mr. Roberts was selected to serve as a director of the Company. There are no relationships between Mr. Moss and Mr. Roberts and the Company or any of its subsidiaries that would require disclosure pursuant to Item 404(a) of Regulation S-K.

    As non-employee directors, each of Mr. Moss and Mr. Roberts will receive cash and equity compensation in accordance with the Company’s Non-Employee Director Compensation Policy. Mr. Moss and Mr. Roberts will receive (A) on the date of their appointment, an initial equity grant consisting of restricted stock units (“RSUs”) with an aggregate grant date fair value of $250,000, which will vest in three substantially equal annual installments subject to their continued service on the Board through such dates and which grant will be subject to stockholder approval in accordance with the rules of the Australian Securities Exchange; and (B) annual cash retainers, payable in monthly installments and prorated for any portion of a month that they are not serving in such positions on the Board or its committees. Further, in accordance with the Company’s Non-Employee Director Compensation Policy, as non-employee directors having served less than six months prior to the Company’s 2025 annual meeting of stockholders, Mr. Moss and Mr. Roberts will each be eligible to receive a prorated annual grant of RSUs, subject to stockholder approval in accordance with the rules of the Australian Securities Exchange, which will vest on the earlier to occur of the first anniversary of the grant date or the date of the Company’s next annual stockholder meeting, subject to their continued service on the Board through such date.

    Effective June 7, 2025 (June 8, 2025 in Australia), the Company entered into indemnification agreements with each of Mr. Moss and Mr. Roberts in the form previously filed as Exhibit 10.2 to the Company’s Form S-1 filed with the Securities and Exchange Commission on November 22, 2024. The indemnification agreement requires the Company to indemnify each of Mr. Moss and Mr. Roberts to the fullest extent permitted under Delaware law against liability that may arise by reason of their service to the Company, and to advance expenses incurred as a result of any proceedings against them as to which they could be indemnified, among other things.

    Resignation of Dr. Wenyi Gu from the Board of Directors

    On June 5, 2025 (June 6, 2025 in Australia), Dr. Wenyi Gu resigned from the Board and as a Class III director with immediate effect. The resignation from the Board was not due to any disagreement with the Company or its management with respect to any matter relating to the Company’s operations, policies or practices.

    The Board thanks Wenyi for his contribution.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    Anteris Technologies Global Corp.
       
    Date: June 9, 2025

     
     
    By:
    /s/ Wayne Paterson
     
    Name:
    Wayne Paterson
     
    Title:
    Chief Executive Officer, Vice Chairman



    Get the next $AVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVR

    DatePrice TargetRatingAnalyst
    1/8/2025$20.00Buy
    Lake Street
    1/7/2025$15.00Buy
    TD Cowen
    1/7/2025$9.00Overweight
    Cantor Fitzgerald
    1/7/2025$22.00Overweight
    Barclays
    More analyst ratings

    $AVR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.

    SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)

    2/5/26 4:06:17 PM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form SCHEDULE 13D filed by Anteris Technologies Global Corp.

    SCHEDULE 13D - Anteris Technologies Global Corp. (0002011514) (Subject)

    1/29/26 5:06:28 PM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 424B3 filed by Anteris Technologies Global Corp.

    424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)

    1/22/26 6:57:51 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

    Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00

    1/8/25 8:52:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Anteris Technologies Global Corp. with a new price target

    TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00

    1/7/25 9:02:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Cantor Fitzgerald initiated coverage on Anteris Technologies Global Corp. with a new price target

    Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00

    1/7/25 9:00:55 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner L1 Capital Pty Ltd bought $28,750,000 worth of shares (5,000,000 units at $5.75) (SEC Form 4)

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    2/9/26 8:49:36 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

    MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ:MDT) (Medtronic), the world's largest medical technology company. The investment closed immediately following Anteris' underwritten offering of common stock, for a combined $320 million in gross proceeds, which supports execution of the global pivotal PARADIGM trial and advan

    1/22/26 4:02:00 PM ET
    $AVR
    $MDT
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

    MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the "Offering") of 40,000,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares from the Company (the "Shares"). The Shares were sold at a public offering price of $5.75 per share. In addition, Anteris today announced the closing of its previously anno

    1/22/26 4:01:00 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

    MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the pricing of its public offering (the "Offering") of 34,782,609 shares of its common stock (the "Shares"). The Shares are being sold at a public offering price of $5.75 per share. The gross proceeds to the Company from the Offering, prior to deducting underwriting discounts, commissions and estimated offering expenses, are expected to be approximately $200 million.

    1/20/26 10:53:47 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner L1 Capital Pty Ltd bought $28,750,000 worth of shares (5,000,000 units at $5.75) (SEC Form 4)

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    2/9/26 8:49:36 PM ET
    $AVR
    Industrial Specialties
    Health Care

    New insider Medtronic Plc claimed ownership of 15,652,173 shares (SEC Form 3)

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    1/29/26 4:11:39 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Chief Operating Officer St Denis David converted options into 166,666 shares and covered exercise/tax liability with 65,584 shares (SEC Form 4)

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    12/18/25 6:30:21 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments